Exploring the salivary proteome following intraglandular mesenchymal stromal cell therapy for radiation-induced hyposalivation in previous head and neck cancer patients: a secondary study protocol for the MESRIX-III, randomised, controlled trial

Q: What type of study is this?

This is a Pre-Registered Trial study.

Christian von Buchwald

doi:10.1186/s13063-025-09074-4

November 28, 2025TrialsOpen Access

Exploring the salivary proteome following intraglandular mesenchymal stromal cell therapy for radiation-induced hyposalivation in previous head and neck cancer patients: a secondary study protocol for the MESRIX-III, randomised, controlled trial

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The MESRIX-III study is approved by the Danish Data Protection Agency (protocol number P-2020-1164), the National Ethics Committee (protocol number: 1802872) and the Danish Medical Agency (2018-000348-24) and is registered at the ClinicalTrials.gov database (NCT04776538). First posted on clinicaltrials.gov 03-JAN-2021.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Christian von Buchwald (2025) studied this question.

synapsesocial.com/papers/692e3d8d6c9b3ab28c1876e6 https://doi.org/10.1186/s13063-025-09074-4

View Full Paper

Ask AI

Bookmark

Share

Exploring the salivary proteome following intraglandular mesenchymal stromal cell therapy for radiation-induced hyposalivation in previous head and neck cancer patients: a secondary study protocol for the MESRIX-III, randomised, controlled trial

Ask about this paper

Abstract

Discussion

Cite This Study

Exploring the salivary proteome following intraglandular mesenchymal stromal cell therapy for radiation-induced hyposalivation in previous head and neck cancer patients: a secondary study protocol for the MESRIX-III, randomised, controlled trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading